Alzheimer's biotech Probiodrug plots a Euro IPO amid a continental boomlet

German drug developer Probiodrug is looking to go public on the Amsterdam exchange, seeking funds to advance its pipeline of treatments for Alzheimer's disease as more and more European biotechs set sights on IPOs. For the moment, Probiodrug is disclosing neither how much it expects to gain in its offering nor just when it plans to stage its debut. The biotech has laid out its use of funds, however, looking to bankroll three treatments that target a particular form of the Alzheimer's-related beta amyloid protein. Its most advanced treatment, the small molecule PQ912, is soon to begin a Phase II trial, and the company has two preclinical candidates with similar targets. Meanwhile, a growing number of private European drugmakers are looking to emulate their U.S. counterparts in a move toward public markets, as France's OSE Pharma, Switzerland's Molecular Partners and others are planning IPOs of their own after a long continental dry spell. News

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.